Get the Stockscreener App
84.63
2.81%
2.31
After Hours:
84.70
0.07
+0.08%
Ani Pharmaceuticals Inc stock is traded at $84.63, with a volume of 340.71K.
It is up +2.81% in the last 24 hours and up +14.04% over the past month.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
See More
Previous Close:
$82.32
Open:
$82.4
24h Volume:
340.71K
Relative Volume:
0.99
Market Cap:
$1.93B
Revenue:
$883.37M
Net Income/Loss:
$71.37M
P/E Ratio:
25.25
EPS:
3.3516
Net Cash Flow:
$150.90M
1W Performance:
+7.81%
1M Performance:
+14.04%
6M Performance:
-8.63%
1Y Performance:
+16.63%
1-Day Range:
$82.26
$84.91
1-Week Range:
$77.14
$84.91
52-Week Range:
$56.71
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Name
Ani Pharmaceuticals Inc
Sector
Phone
(218) 634-3500
Address
210 MAIN STREET WEST, BAUDETTE, MN
Compare ANIP vs TAK, ZTS, TEVA, HLN, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
84.63 | 1.87B | 883.37M | 71.37M | 150.90M | 3.3516 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | H.C. Wainwright | Buy |
| Mar-14-25 | Initiated | Jefferies | Buy |
| Mar-12-25 | Initiated | JP Morgan | Overweight |
| Dec-11-24 | Initiated | Leerink Partners | Outperform |
| Oct-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-15-24 | Initiated | CapitalOne | Overweight |
| Aug-22-23 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Sep-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-02-21 | Initiated | Truist | Buy |
| May-07-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| May-10-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-16-17 | Reiterated | Canaccord Genuity | Buy |
| Jul-31-17 | Initiated | Canaccord Genuity | Buy |
| Feb-22-17 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-23-16 | Initiated | Raymond James | Strong Buy |
| May-24-16 | Downgrade | Standpoint Research | Buy → Hold |
| Nov-13-15 | Initiated | Standpoint Research | Buy |
| Sep-28-15 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
| Aug-04-15 | Reiterated | ROTH Capital | Neutral |
| Jul-31-15 | Reiterated | Oppenheimer | Outperform |
| Jul-15-15 | Reiterated | ROTH Capital | Neutral |
| Jun-23-15 | Reiterated | Oppenheimer | Outperform |
| May-18-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Reiterated | Oppenheimer | Outperform |
| Apr-10-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-26-15 | Reiterated | ROTH Capital | Buy |
| Feb-18-15 | Reiterated | Oppenheimer | Outperform |
View All
Ani Pharmaceuticals Inc Stock (ANIP) Latest News
MSN Money - MSN
Hussman Strategic Advisors Inc. Takes Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Artemis Investment Management LLP Invests $1.71 Million in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
ANI Pharmaceuticals (ANIP) Announces Launch of Pimozide Tablets 1 mg and 2 mg - Insider Monkey
ANI Pharmaceuticals (ANIP) Expected to Announce Earnings on Friday - MarketBeat
Zacks.com featured highlights include Mirion Technologies, Intuit and ANI Pharmaceuticals - Yahoo Finance
9 Best Drug Stocks to Buy According to Analysts - Insider Monkey
NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLA - TradingView
ANI Pharmaceuticals rolls out generic carbamazepine extended-release capsules - MSN
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
What ANI Pharmaceuticals (ANIP)'s Niche CNS Generic Launches Mean For Its Specialty-First Strategy - Sahm
Assessing ANI Pharmaceuticals (ANIP) Valuation After New U.S. Generic Drug Launches - Yahoo Finance
Organon Shares Rally 16% in Premarket as Sun Pharma Announces Buyout - TradingView
ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET - marketscreener.com
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Passes Below 200-Day Moving AverageHere's Why - MarketBeat
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Momentum Stock - Yahoo Finance
How Investors Are Reacting To ANI Pharmaceuticals (ANIP) New Generics Push And ILUVIEN Trial Data - Sahm
ANI Pharmaceuticals launches generic pimozide tablets By Investing.com - Investing.com India
ANI Pharmaceuticals' 2026 Catalysts Include Gout Push and New Generics - Yahoo Finance
Is ANIP Stock Undervalued at 10x Forward Earnings and $93 Target? - TradingView
ANIP's Cortrophin Gel Surge Powers 2026 Growth Outlook - Yahoo Finance
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock - Yahoo Finance
ANI Pharmaceuticals launches generic pimozide tablets - Investing.com
ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity - The Manila Times
ANI Pharma (ANIP) Stock: Invest or Wait? (+3.65%) 2026-04-18Stop Loss Levels - Cổng thông tin điện tử tỉnh Lào Cai
ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded by Zacks Research to Strong-Buy Rating - MarketBeat
Analysts Offer Insights on Healthcare Companies: Ceribell, Inc. (CBLL), ANI Pharmaceuticals (ANIP) and Amylyx Pharmaceuticals Inc (AMLX) - The Globe and Mail
ANI Pharmaceuticals News Highlights Undervalued Shares And New Specialty Generics - Sahm
Assessing ANI Pharmaceuticals (ANIP) Valuation After Recent Mixed Share Price Performance - Sahm
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
ANI Pharmaceuticals Launches Carbamazepine Extended-Release Capsules - Intellectia AI
ANI Pharmaceuticals launches generic carbamazepine capsules By Investing.com - Investing.com India
ANIP News | ANI PHARMACEUTICALS INC (NASDAQ:ANIP) - ChartMill
Ani Pharmaceuticals’ Cook sells $38k in stock - Investing.com
Ani Pharmaceuticals Inc Stock (ANIP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
2.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):